Sappi Casting and Release Announces New Laminate Surface With Superior Aesthetics, Texture and Performance: Arrio™
26.4.2022 11:00:00 EEST | Business Wire | Press release
Sappi, a leading producer and supplier of diversified paper, packaging products and dissolving pulp, today launched Arrio, a decorative laminate surface solution that delivers remarkable aesthetics, premium haptics and scratch and fingerprint resistance for high-wear surfaces. By designing Arrio to serve the unmet needs of customers, Sappi will now become the only company that provides high-fidelity, 100% replicated textured finished surfaces available in flat, then expanding to include a 3D texture library over time.
With its durable acrylic surface, Arrio provides extraordinarily detailed, realistic finished surfaces that will eventually support multiple textures and décor colors, gloss effects, varying depths and visible contrast. Sappi’s high-precision manufacturing process generates the exact same surface finish over time without variation or loss of definition. Arrio, which offers a superior surface to conventional melamine in aesthetics and performance, is a perfect solution for decorative and functional surfaces on furniture, work surfaces, kitchen cabinetry and more.
“We are excited to introduce Arrio, which is not a mold that imparts texture, but is the actual finished surface,” said Mark Hittie, Director of Release Strategy, Sappi Casting and Release. “Arrio comes from Sappi’s spirit and core competence: we make texture, we drive texture. It’s another example of Sappi delivering a high-quality and innovative product that outperforms traditional options, reduces cost and opens up a range of possibilities for consumers. We’re also proud that Sappi created Arrio with sustainability in mind. The durable acrylic surface extends product lifetime and does not require application or removal of protective film layers, thus reducing manufacturing costs and waste.”
Unlike surfaces produced with an excimer process, Arrio will offer a uniquely customizable surface texture, including various flat finishes and textures with multiple gloss levels, such as wood or stone designs. The manufacturing process provides 100% consistency, order to order, in texture, gloss, touch and function. Arrio provides a superior solution over existing concepts because of its endless potential for customization. It also provides superior haptics, including super matte, smooth touch and high-color intensity surfaces, and it is suitable for single radius wrapping applications.
Arrio also offers significantly lower investment costs for glued and pressed finished surfaces due to manufacturers’ savings and efficiencies in the handling, shipping and layup processes.
Offered initially in a supermatte, fingerprint resistant, soft touch texture called Matte Haven on black décor, the Arrio platform will continue to develop with the future addition of texture and décor color options.
Sappi’s forward-looking products and textures continue to leverage state-of-the-art technology from its Westbrook Mill in Maine. Sappi has been at the forefront of technological innovation and evolution in the release paper industry with nearly 80 years of experience creating textures.
To request a launch kit for Arrio, please contact your Sappi sales representative. To learn more about Arrio and Sappi’s casting and release papers, please visit: www.sappi.com/sappi-casting-release-papers.
About Sappi North America, Inc.
Sappi North America, Inc., headquartered in Boston, is a market leader in converting wood fiber into superior products that customers demand worldwide. The success of our diversified businesses – high-quality Coated Graphic Papers, Dissolving Pulp, and Packaging and Specialty Papers – is driven by strong customer relationships, best-in-class people and advantaged assets, products and services. Our high-quality Graphic Papers, including McCoy, Opus, Somerset and Flo, are the key platform for premium magazines, catalogs, books, direct mail and high-end print advertising. We are a leading manufacturer of Dissolving Pulp with our Verve brand, a sustainable fiber that is used in a wide range of products, including textile fibers and household goods. We deliver sustainable Packaging and Specialty Papers for luxury packaging and folding carton applications with our single-ply packaging brands, Spectro and Proto, and for the food and label industries with our specialty paper, LusterCote. We are also one of the world's leading suppliers of Casting and Release Papers with our Ultracast, PolyEx and Classics lines for the automotive, fashion and engineered films industries. Customers rely on Sappi for high technical, operational and market expertise; products and services delivered with consistently high quality and reliability; and, state-of-the-art and cost-competitive assets and innovative spirit.
Sappi North America is a subsidiary of Sappi Limited (JSE), a global company headquartered in Johannesburg, South Africa, with more than 12,000 employees and manufacturing operations on three continents in seven countries and customers in over 150 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005523/en/
Contact information
Peter Steele
Sappi North America
+1 617-423-5409
peter.steele@sappi.com
Matter Communications
+1 971-245-3613
Sappi@matternow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
